High Prevalence Of Hiv Around The Globe Is Boosting The Growth Of The Toxoplasmosis Treatment Drugs Market
In February 2020, The U.S. Food and Drug Administration has approved an application for the first generic of Daraprim (pyrimethamine) tablets for the treatment of toxoplasmosis (an infection caused by the parasite Toxoplasma gondii) when used with a sulfonamide (a group of medicines used to treat bacterial infections). The rising prevalence of HIV around the globe is increasing the risk of toxoplasma gonad infection. This is contributing to the growth of the toxoplasmosis treatment drugs market . According to the HIV.gov Mission & Team, there were approximately 38 million people across the globe with HIV/AIDS in 2019. Of these, 36.2 million were adults and 1.8 million were children (<15 years old). Moreover, growing research and development activities by pharma companies for toxoplasmosis are again fostering the growth of the toxoplasmosis treatment drugs market. For example, in 2018, Vyera Pharmaceuticals LLC received the U.S. Food Drug and Administration (FDA) approval...